Phenobarbital, by inducing liver microsomal enzymes, may affect bile acid synthesis from cholesterol and thus alter the secretion of biliary lipids and the composition of bile. We, therefore, determined the effects of phenobarbital on bile flow, biliary lipid secretion, bile acid synthesis, and bile-acid pool size. Using an experimental preparation that allows controlled interruption of the enterohepatic circulation (1), we administered 5 mg/kg per day of phenobarbital to healthy Rhesus monkeys for 1-2 wk to achieve steady-state conditions. Three animals were studied with an intact enterohepatic circulation and three with a total bile fistula, each animal served as its own control. Total bile flow and secretion of bile salt, phospholipid, and cholesterol were measured every 24 h during steady-state conditions. Further, under conditions of an intact enterohepatic circulation bile-acid synthetic rate was measured in three animals and pool size estimated in two animals during both control and drug treatment periods.

Phenobarbital at doses of 5 mg/kg per day increased bile flow 30-50% in all animals ($P < 0.001$). The increased bile flow resulted from both an increased “bile-salt independent fraction” and an increased bile-salt secretion rate. Phenobarbital significantly increased bile salt ($P < 0.01$) and phospholipid secretion ($P < 0.05$) by about 30% but cholesterol secretion was not significantly changed. Consequently, the concentration of cholesterol relative to bile salt and […]

Find the latest version:

http://jci.me/107160/pdf
Primate Biliary Physiology VIII

THE EFFECT OF PHENOBARBITAL UPON BILE SALT SYNTHESIS AND POOL SIZE, BILIARY LIPID SECRETION, AND BILE COMPOSITION

RICHARD N. REDINGER and DONALD M. SMALL

From the Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118

ABSTRACT Phenobarbital, by inducing liver microsomal enzymes, may affect bile acid synthesis from cholesterol and thus alter the secretion of biliary lipids and the composition of bile. We, therefore, determined the effects of phenobarbital on bile flow, biliary lipid secretion, bile acid synthesis, and bile-acid pool size. Using an experimental preparation that allows controlled interruption of the enterohepatic circulation (1), we administered 5 mg/kg per day of phenobarbital to healthy Rhesus monkeys for 1-2 wk to achieve steady-state conditions. Three animals were studied with an intact enterohepatic circulation and three with a total bile fistula, each animal served as its own control. Total bile flow and secretion of bile salt, phospholipid, and cholesterol were measured every 24 h during steady-state conditions. Further, under conditions of an intact enterohepatic circulation bile-acid synthetic rate was measured in three animals and pool size estimated in two animals during both control and drug treatment periods.

Phenobarbital at doses of 5 mg/kg per day increased bile flow 30-50% in all animals (P < 0.001). The increased bile flow resulted from both an increased “bile-salt independent fraction” and an increased bile-salt secretion rate. Phenobarbital significantly increased bile salt (P < 0.01) and phospholipid secretion (P < 0.05) by about 30% but cholesterol secretion was not significantly changed. Consequently, the concentration of cholesterol relative to bile salt and phospholipid was decreased (P < 0.001). Phenobarbital significantly enhanced the maximal rate of bile acid synthesis 25-30% in all three monkeys with total bile fistulas (P < 0.05) and also augmented bile acid synthesis and pool size in animals with intact enterohepatic circulations despite the fact that the rates of bile salt returning to the liver in these animals would have inhibited bile acid synthesis in control animals. Thus, phenobarbital not only increases the maximal rate of bile acid synthesis but also alters the normal control mechanisms by which bile salts returning to the liver inhibit bile salt synthesis. The fact that phenobarbital treatment results in increased synthesis of bile salt and unchanged secretion of cholesterol is consistent with the view that the drug augments conversion of hepatic cholesterol to bile salt. The resulting decrease in relative cholesterol content in bile may have therapeutic implications for cholesterol gallstone therapy.

INTRODUCTION

The enterohepatic circulation (EHC)\(^1\) of bile salts begins with the synthesis of bile acids from cholesterol within the liver. Bile acids are then conjugated with glycine or taurine, secreted by the liver as bile salts into bile, and ultimately pass into the upper intestine. They then move down the small intestine and are absorbed partly from the upper small bowel by passive diffusion and from the ileum by a combination of active and pas-

\(^1\) Abbreviation used in this paper: EHC, enterohepatic circulation.

The Journal of Clinical Investigation Volume 52 January 1973 161
sive processes. After passing through the intestinal mucosal cells they return to the liver via the portal vein to complete the EHC. Normally, only a small amount of bile salt escapes absorption and is lost in feces. Thus, in a steady state, the body needs only to synthesize that amount of bile salt lost to maintain a constant bile-salt secretion rate and pool size (1).

In animals with a total bile fistula, bile acid synthesis is enhanced (1, 2). Furthermore, it has been demonstrated in the Rhesus monkey that bile acid synthesis in animals with an intact EHC (normal state) is low but increases in proportion to bile salt loss produced by a partial bile fistula (1). Thus, bile salt secretion (total quantity of bile salt leaving the liver per 24 h) and bile salt pool are maintained in the face of increased bile salt loss up to a certain point by a compensatory increase in bile salt synthesis. Although bile acid synthesis can, in fact, increase about 10-fold in response to bile salt loss, it cannot compensate adequately when the loss is great. Thus, when one-third or more of total bile salt secretion is diverted from the animal, bile acid synthesis, although maximal, cannot make up for loss and consequently both total bile salt secretion and pool are decreased (7). Shefer, Hauser, Bekersky, and Mosbach (3) have recently shown that the rate-limiting step in the synthesis of bile acid from cholesterol is the conversion of cholesterol to 7α-hydroxycholesterol by the microsomal enzyme cholesterol 7α-hydroxylase. Furthermore, 7α-hydroxylation is normally significantly suppressed by feedback inhibition of bile salt returned to the liver via the portal vein (4).

Phenobarbital, a well-known microsomal enzyme inducer (5), can affect bile acid synthesis from cholesterol by altering the activity of the enzyme cholesterol 7α-hydroxylase (6). It is also known that hepatic phospholipid content and synthesis are increased in proliferating endoplasmic reticulum of rats pretreated with phenobarbital (7, 8). If the hepatic metabolism of bile salt, phospholipid, and cholesterol were altered by phenobarbital then the secretion of these lipids might also be altered. If the secretion rate of any lipid is altered out of proportion to that of the other lipids, the composition of bile relative to bile salt, phospholipid, and cholesterol would also be changed. It is, therefore, possible that phenobarbital treatment increases bile salt synthesis from cholesterol and causes increased bile salt and decreased cholesterol secretion. Furthermore, if the increased phospholipid synthesis also resulted in increased phospholipid secretion then the bile secreted by phenobarbital-treated animals ought to have significantly more bile salt and phospholipid but less cholesterol. Since this hypothesis cannot easily be tested in man, we utilized a chronic monkey model developed in our laboratory (9, 10) to study the effects of phenobarbital administration upon bile salt metabolism and biliary lipid secretion.

Specifically, we will discuss the effects of phenobarbital on bile acid synthesis in: (a) animals with total bile fistula who, before administration of drug, had achieved maximal bile acid synthesis and in: (b) animals with physiologically intact EHC who normally have a low rate of bile salt synthesis. We will then discuss the effects of phenobarbital upon total bile salt, phospholipid, and cholesterol secretion in animals with total bile fistula as well as those with intact EHC.

**METHODS**

**Experimental model**

A description of the primate model together with details of animal management (1, 9), mechanical and electronic design of the apparatus (10) have been published. Briefly, healthy Rhesus monkeys of both sexes were trained to sit in restraining chairs for a period of 2–3 wk before surgical implantation of biliary and duodenal fistulas. The resultant exteriorized EHC allowed bile to pass from the biliary t-tube through an electronic stream-splitter which continuously sampled a given fraction of secreted bile. The remainder of the secreted bile was simultaneously returned to the duodenum. The animals were allowed 3–5 wk to recover from surgery and were then studied under steady-state conditions.2

Two extreme states of the EHC were studied: complete diversion of bile (total bile fistula) and "intact" EHC. In total interruption of the EHC by bile fistula no bile salt returned to the intestine, none was reabsorbed, and, therefore, none returned to the liver. Under steady-state conditions, bile acid synthesis was high—approximately 2 mmol/24 h per animal (1). On the other hand, if only 5% of the diverted bile was collected and 95% simultaneously returned to the duodenum, the EHC could be considered physiologically "intact." In fact it has been shown that bile flow and biliary lipid secretion rates, that is, the total output from the liver per 24 h of bile salt (1), phospholipid (11), and cholesterol (11) are not significantly altered by this small (5%) interruption of the EHC. Thus, using the chronic monkey model the following parameters could be determined accurately: (a) the total secretion per 24 h by the liver of bile salt, phospholipid, and cholesterol from the respective bile salt, phospholipid, and cholesterol concentration and volume of the bile sample collected over 24 h: (b) the amount of the bile salt (or other biliary constituent) returned to the duodenum per 24 h which equals the amount of bile salt secreted by the liver minus the amount of bile salt collected in the sample: (c) the amount of bile salt absorbed and returned to the liver via the portal vein per 24 h which equals the amount of bile salt entering the intestine minus the daily fecal bile salt loss, and: (d) the amount of bile acid synthesized per 24 h in the steady state which equals the total loss of bile salt per diem (i.e., the amount of bile salt in the collected sample plus the fecal loss per 24 h).

2 Steady-state conditions occur in those animals maintaining constant body weight on a constant caloric intake and who exhibit steady daily bile flow and bile-salt secretion rates.
Experimental design, sample collection, and expression of results. All studies were carried out during steady-state conditions with each animal acting as its own control. Animals consumed 120-180 g or 500-750 cal of Purina Monkey Chow per day (Ralston Purina, St. Louis, Mo.), which contained 62% carbohydrate, 15% protein, 2.5% fiber, 9% water, and 4.8% ash. Total lipid content determined in our laboratory on repeated occasions from different lots varied from 5.5 to 6.2% (mean 5.6). These lipids were comprised mainly of triglycerides (96%) and fatty acids (4%). Total sterol content was less than 0.1% of total lipid. Thus, animals consumed between 6.7 to 10.0 g (mean 8.4 g) or 60-90 cal (mean 75) total lipid, virtually all as triglyceride and fatty acid and less than 10 mg total sterol per day.

Three animals with chronic total bile fistula and three animals with an intact EHC were studied. Predrug control periods of sufficient time (usually 5-7 days) were carried out to insure steady daily bile flow and biliary bile-salt secretion rates. Bile samples were collected over a 24 h period and then stored at -20°C. Sodium phenobarbital, 5 mg/kg per day, was then administered via the duodenal fistula to each animal three times per day in equally divided doses. The drug was administered until at least 4 consecutive days of steady-state conditions were achieved. Between 2 and 3 days were needed to reach the new steady state. After cessation of phenobarbital the animals were allowed to reach a new steady state. Usually 2-3 days were needed to reach this postdrug control steady state but one animal took 7 days to return to precontrol values. To judge the consistency of drug response, one animal with an intact EHC was given phenobarbital on three separate occasions. Each steady-state drug period was separated by a steady-state control period. Thus four control and three drug periods were carried out.

In two animals with intact EHC, bile-salt synthetic rates and bile-salt pool size were determined during control periods and then repeated after the animal had reached a new steady state on drug treatment. Bile salt pool sizes were determined by the washout technique of Dowling, Mack, and Small (1). Biliary lipid composition was expressed as the relative molar concentrations of biliary salt, phospholipid, and cholesterol according to the method of Admirand and Small (13). Feces were collected daily and stored at -20°C in plastic bags. Later 2- to 3-day fecal periods were thawed, homogenized with 2 parts water, and a 30 cm² portion sonicated (12) before bile acid analysis.

Laboratory procedures. Biliary bile salt was measured by the hydroxysteroid method of Talalay (14) as modified by Admirand and Small (13). Phospholipid was determined as inorganic phosphorus by the method of Bartlett (15). Cholesterol was measured by a modification of the method of Schoenheimer and Sperry (16). Bile (0.5 ml) was added to 4.5 ml of isopropl alcohol, shaken vigorously for 60 s, and the precipitated protein and pigment spun down by centrifugation at 1500 rpm for 10 min. The digitonin precipitate was washed with acetone to remove any remaining pigment when necessary.

Fecal bile acids were extracted by the method of Evrard and Janssen (17) and measured by the method of Sandberg, Sjovall, Sjovall, and Turner (18) with the following minor modifications. An initial extraction of the fecal portion with 0.5 N HCl in absolute alcohol was carried out to insure adequate extraction of conjugated bile acids from feces as described by Manes and Schneider (19). The final extract in benzene was purified by using a silicic acid column according to the method of Eneroth, Hellstrom, and Sjovall (20). Tracer doses of radioactive cholic, deoxycholic, or lithocholic acid were used as internal standards and recoveries of 84.4-100% (mean 92%) were accepted. TFA derivatives of bile-acid methyl esters were run on a Packard gas chromatogram, model 7401/562 with hydrogen flame ionization detector (Packard Instrument Co., Downers Grove, Ill). 4-fm columns packed with 1% QF-1 on Gas-chrom Q (Applied Science Labs, Inc, State College, Pa.) were maintained at 230°C during bile acid determinations. Bile acids were quantitated by means of planimetry by comparing areas under peaks from unknown samples, to that of a known cholic acid standard.

Statistical analysis

In each individual animal the differences between control and drug periods were analyzed by Student's t test method (21). The overall data for all monkeys were analyzed by an analysis of variance for a 2 × 2 factorial arrangement of treatments. Since the number of observations (n) in the subgroups was not equal, an approximate method using unweighted means and the harmonic mean of the n was used (see pages 385-386, reference 21).

RESULTS

Bile salt synthesis and pool size

Animals with total bile fistula (100% bile diversion). The effect of phenobarbital is illustrated in one animal in Fig. 1. In the predrug control period the synthetic rate (mean ±1 SEM) was 1.95±0.16 mmol/24 h. After days treatment the animal reached a new steady-state rate of 2.46±0.06 mmol/24 h. 2 days after stopping the drug the synthetic rate returned to 1.91±0.07 mmol/24 h a value indistinguishable from the pre-drug control. The results for all three animals are given in Table I. Phenobarbital increased the level of bile acid synthesis in every

![Figure 1 Bile acid synthesis before, during, and after phenobarbital treatment](https://example.com/figure1.png)

Figure 1 Bile acid synthesis before, during, and after phenobarbital treatment. The bars represent the mean synthetic rate ±ISEM of a 5 day steady-state predrug control period, a 5 day steady-state drug treatment period, and a 7 day steady-state postdrug control period. Numbers in bars refer to number of observations in each period. While on phenobarbital the synthetic rate was significantly greater than during either the predrug control period (P < 0.05) or postdrug control period (P < 0.01). The two control periods were not statistically different.

Effects of Phenobarbital on Bile Salt and Biliary Lipid Metabolism
animal with a total bile fistula (P < 0.05 or better),
even though these animals were at maximal bile acid
synthesis before drug treatment.

Animals with intact EHC (5% bile diversion). In
Table II the effects of phenobarbital on several aspects of
bile salt metabolism in the three animals studied with
an intact EHC (5% bile diversion) is given and the
methods for measuring synthesis demonstrated, Columns
1 to 5 give in succession the amount of bile salt in the
collected sample, returned to the duodenum, secreted,
lost in feces, and absorbed and returned to the liver,
respectively. Column 6 gives the percent of bile enter-
ing the intestine which is readsorbed in the steady state.

The percent readsorbed varied from animal to animal
but all three animals absorbed somewhat more effi-
ciently while on the drug. Bile acid synthesis was sig-
nificantly enhanced by phenobarbital in all three animals
(Table II, column 7). In animals B and D the pool size
during the control period was 0.639 and 0.640 mmol
respectively. The pool was increased by phenobarbital to
0.720 mmol in animal B and to 1.130 mmol in animal D.

Bile flow and biliary bile salt, phospholipid, and
cholesterol secretion

Animals with total bile fistula (100% bile diversion).
The results for bile blow and biliary lipid secretion rates
per 24 h carried out in three animals with bile fistula are
given for each animal in Fig. 2. The height of the histo-
grams represent the mean bile flow or secretion rates of
control and drug treatment period and the vertical bar
±1 SEM. Phenobarbital treatment increased bile flow
significantly (P < 0.002 or better) in each animal.
Bile salt and phospholipid secretion rates were also in-
creased by the drug in all studies (P < 0.05 or better).
On the other hand, cholesterol secretion rate was de-
creased in one animal (animal A) but unchanged in the
other two.

Animals with intact EHC (5% bile diversion). To as-
se the consistency of response to phenobarbital, one
animal was treated on three separate occasions with the

| Table I

Daily Bile Acid Synthesis in Animals with Total Bile Fistulas

<table>
<thead>
<tr>
<th>Animal</th>
<th>Control n</th>
<th>Phenobarbital n</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mmol/24 h</td>
<td>mmol/24 h</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>1.66(0.13)</td>
<td>2.28(0.06)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>B</td>
<td>2.03(0.35)</td>
<td>2.60(0.08)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>C</td>
<td>1.93(0.16)</td>
<td>2.46(0.06)</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>

During both control and phenobarbital periods, animals were in a steady-
state condition and n refers to the total number of 24-h study periods for
each experiment. The numbers in brackets refer to the SEM for each study.
Thus, animals already having a maximal bile-acid synthetic rate during
control periods increased their bile-acid synthetic rate significantly while
on phenobarbital in each study.

| Table II

Effect of Phenobarbital on Bile Salt Metabolism in Animals with Intact EHC

<table>
<thead>
<tr>
<th>Column</th>
<th>Steady-state periods</th>
<th>BS* in sample</th>
<th>BS* returned to animal</th>
<th>BS* secretion</th>
<th>BS* loss in feces</th>
<th>BS* absorbed and returned to liver</th>
<th>BS* entering intestine</th>
<th>Bile acid synthesis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(number of 24-h study periods)</td>
<td>5% of secretion</td>
<td>95% of secretion</td>
<td>secretion</td>
<td>in feces</td>
<td>to liver</td>
<td>entering intestine</td>
<td>synthesis</td>
</tr>
<tr>
<td>A</td>
<td>Control</td>
<td>6</td>
<td>0.42(0.022)</td>
<td>8.04</td>
<td>8.46</td>
<td>0.125</td>
<td>9.71</td>
<td>98.4</td>
</tr>
<tr>
<td>Drug</td>
<td>11</td>
<td>0.500(0.025)</td>
<td>9.35</td>
<td>10.03</td>
<td>0.125</td>
<td>9.43</td>
<td>98.0</td>
<td>0.628(0.025)</td>
</tr>
<tr>
<td>B</td>
<td>Control</td>
<td>3</td>
<td>0.397(0.029)</td>
<td>7.55</td>
<td>7.95</td>
<td>0.115</td>
<td>7.40</td>
<td>98.5</td>
</tr>
<tr>
<td>Drug</td>
<td>5</td>
<td>0.616(0.033)</td>
<td>11.71</td>
<td>12.33</td>
<td>0.122</td>
<td>11.59</td>
<td>99.0</td>
<td>0.739(0.033)</td>
</tr>
<tr>
<td>C</td>
<td>Control</td>
<td>19</td>
<td>0.550(0.018)</td>
<td>10.45</td>
<td>11.00</td>
<td>0.130</td>
<td>10.32</td>
<td>98.8</td>
</tr>
<tr>
<td>Drug</td>
<td>18</td>
<td>0.710(0.017)</td>
<td>13.50</td>
<td>14.21</td>
<td>0.135</td>
<td>13.38</td>
<td>99.2</td>
<td>0.835(0.017)</td>
</tr>
</tbody>
</table>

In these experiments 5% of the total volume of bile secreted is collected for analysis and the rest (95%) returned to the animal. Mean values for control
vs. phenobarbital periods are shown. Column 1 is the quantity of bile salt in the collected sample. Column 2 is the quantity of bile salt returned to the
duodenum. Column 3, the total daily bile salt secretion equals column 1 plus 2. Column 5 is the amount of bile salt absorbed and returned to the liver via
the portal vein (mmol/24 h) and is derived by subtracting daily fecal bile salt losses (column 4) from the amount of bile salt which entered the intestine
(column 2). Column 6 is the percent readsorption of bile salt. Under steady-state conditions, bile acid synthesis equals total bile salt loss. Thus, daily bile
acid synthesis, column 7, is the sum of bile salt loss in the collected sample plus the fecal loss. Synthesis was significantly increased in each animal (P < 0.05
or better) when on phenobarbital.

* BS, bile salt.
† Mean ±1 SEM.
‡ Calculated mean fecal bile salts losses. These values were taken from the mean of the fecal loss in all other experiments. No difference was found between
fecal excretion during control or phenobarbital periods.

164 R. N. Redinger and D. M. Small
same dose of the drug (5 mg/kg per 24 h). Each drug period was separated by a steady-state control period. In Fig. 3 the bile flow and bile-salt secretion rate for the four control periods and three drug treatment periods are shown. Except for the first predrug control period bile flow was always significantly lower in the control period compared with the drug treatment period. The bile-salt secretion rates behaved in a consistent manner. Each drug period showed a significantly higher secretion rate ($P < 0.05$ or better) than either the control before or after. 2–3 days of nonsteady-state conditions separated each steady-state period. The results for bile flow and biliary lipid secretion for all three animals are summarized in Fig. 4. As in studies with complete biliary diversion, all animals with a physiologically intact EHC also experienced significantly increased bile flow when treated with phenobarbital ($P < 0.001$). Bile-salt secretion rates were also increased by phenobarbital treatment in all studies of animals with intact EHC ($P < 0.05$ or better). Phospholipid secretion was also significantly increased in all animals ($P < 0.01$ or better) but cholesterol secretion was not significantly changed by drug treatment.

Relative concentrations of bile salt, phospholipid, and cholesterol in bile

Table III summarizes the results from animals with total bile fistula and intact EHC, showing the changes in bile composition resulting from phenobarbital administration. Whereas no consistent effects were noted in the relative proportions of bile salt or phospholipid in either 100% biliary diversion or "intact" EHC animals, a consistent decrease in the relative proportion of cholesterol in bile was found in every study. In three studies the decrease was significant ($P < 0.05$ or better) and in the other three studies the decrease was not significant. In addition, bile salt to cholesterol ratios were increased in every study.

Effects of Phenobarbital on Bile Salt and Biliary Lipid Metabolism
Overall statistical analysis of bile flow, lipid secretion, and relative composition

Because of limitations in experimental technique the numbers of observations in the control and drug treatment subgroups were not the same. Thus the statistical analysis was handled in an unusual way (see methods). By analysis of variance of a $2 \times 2$ factorial arrangement of treatments we could draw the following conclusions (Table IV). First, in no case was there significant interaction. That is, any difference between intact EHC and bile fistula holds for controls as well as for drug treatment and any difference between controls and drug treatment holds for animals with total bile fistula as well as animals with an intact EHC. Second, in every case the difference between total bile fistula and an intact EHC is significant with a $P < 0.001$. This conclusion was reached in earlier studies on other monkeys by different statistical techniques (1, 11). Third, phenobarbital significantly increased bile flow ($P < 0.001$), bile salt secretion ($P < 0.01$), and phospholipid secretion ($P < 0.05$) above control values both in animals with bile fistulas and with intact EHC. In contrast, cholesterol secretion was not significantly altered. Finally phenobarbital significantly decreased the proportion of cholesterol in bile in both groups of animals ($P < 0.001$) but failed to significantly alter the proportion of bile salts or phospholipids.

DISCUSSION

Phenobarbital enhances bile flow in several species (22–25). We have now found that bile flow is increased during steady-state conditions in the bile-diverted monkey as well as in the monkey with an intact EHC. The mechanism by which phenobarbital-induced hypercholesterolemia occurs has been a matter of speculation. It has been proposed that the osmotic effect produced by the active transport of bile acid anions out of the liver cell results in increased water and solute movement from the liver cell into the bile canaliculus (26). Thus, phenobarbital may increase bile flow by increasing bile salt secretion from the liver. Berthelot, Erlinger, Dhumexaux, and Preaux (27) have concluded from experiments in the rat, however, that the phenobarbital-induced increase in bile flow was due to the secretion of a bile-salt independent fraction of water in bile. On a plot of bile flow vs. bile-salt secretion rates, (Fig. 5) our control animals have a bile-salt independent fraction of approximately 70 cm$^3$/24 h ($y$ intercept at $x = 0$), a value very similar to values (71.7 cm$^3$) for other Rhesus monkeys studied earlier in this laboratory (9). Phenobarbital-treated animals, however, secreted a bile-salt independent fraction of 102 cm$^3$/24 h. Therefore, there is an increase in the bile-salt independent fraction of bile flow in phenobarbital-treated animals. Since the slopes of the two lines were not significantly different, phenobarbital did not increase the amount of water secreted per mole of bile salt.
secreted. However, we also found that phenobarbital increased total bile salt secretion over control values in all animals. We therefore conclude that the increased bile flow in phenobarbital-treated animals is the result of two processes: (a) increased bile-salt independent flow and (b) increased bile-salt secretion rates.

Since our experiments were carried out during steady-state conditions we avoided the problems associated with surgery (28), fasting (29), and interruption of the EHC, all of which have major effects on bile salt metabolism in the monkey. In addition to using a different species, we also employed a much smaller dose of phenobarbital than did Berthelot et al. (27) (5 mg/kg per day per animal vs. 100 mg/kg per day per animal). The dose we used, when compared with humans on a weight for weight basis, is close to that therapeutically employed for man (30). In fact, when we used doses as high as 30 mg/kg per day in two monkeys, these animals became ill and eventually experienced decreased bile formation. Thus, in monkeys under conditions of our experiments, phenobarbital in moderate doses increased both the bile-salt independent fraction of bile flow and the bile-salt secretion-dependent fraction.

Evidence for and against phenobarbital induction of 7a-hydroxylation of cholesterol, the rate-limiting step in the conversion of cholesterol to bile salt, is present in the literature. Wada, Hirata, Nakao, and Sakamoto (31) have reported that 7a-hydroxylation of cholesterol was greater in hepatic microsomal preparations from phenobarbital-treated Sprague-Dawley rats (0.1% phenobarbital in diet) compared with control rats. Furthermore, this reaction was inhibited by carbon monoxide suggesting involvement of the electron transport system which functions in the induction of enzymes involved in the hydroxylation of many other drugs (32-36) and steroids (37, 38). Shefer, Hauser, and Mosbach (6) found that phenobarbital given intraperitonally (100 mg/kg) enhanced microsomal 7a-hydroxylation of cholesterol sixfold in Wistar but not Sprague-Dawley rats. Furthermore Einarsson and Johansson (39) concluded from enzyme studies of Sprague-Dawley rat hepatic-microsomal preparations that neither 7a-hydroxy-

**Figure 4** The effect of phenobarbital on bile flow and secretion rates of biliary lipids in animals with an intact EHC. The height of the histograms, represent the mean for control vs. phenobarbital periods in each animal for bile flow, and secretion rates of bile salt, phospholipid, and cholesterol. The vertical bar is ±SEM. P values were determined by Student's t test (21). Increases in bile flow as well as bile salt and phospholipid secretion rates were found in all studies, while cholesterol secretion rate was unchanged.

**Effects of Phenobarbital on Bile Salt and Biliary Lipid Metabolism**

![Graph showing bile flow and secretion rates](image-url)
TABLE III
Relative Composition and Bile Salt to Cholesterol Ratios in Animals with Total Bile Fistula and with an Intact EHC

<table>
<thead>
<tr>
<th>Animal</th>
<th>Study period (n)</th>
<th>Relative composition (moles, %)</th>
<th>Bile salt to Cholesterol ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Bile salt</td>
<td>Phospholipid</td>
</tr>
<tr>
<td>A</td>
<td>Total bile fistula</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control (5)</td>
<td>75.85(1.94)</td>
<td>19.6 (1.4)</td>
<td>NS</td>
</tr>
<tr>
<td>Drug (7)</td>
<td>78.64(0.70)</td>
<td>19.2 (0.66)</td>
<td>NS</td>
</tr>
<tr>
<td>B</td>
<td>Control (4)</td>
<td>79.69(0.59)</td>
<td>17.90(0.53)</td>
</tr>
<tr>
<td>Drug (4)</td>
<td>78.41(1.60)</td>
<td>19.06(1.34)</td>
<td>1.98(0.25)</td>
</tr>
<tr>
<td>C</td>
<td>Control (5)</td>
<td>80.76(1.15)</td>
<td>16.79(0.89)</td>
</tr>
<tr>
<td>Drug (5)</td>
<td>78.49(0.74)</td>
<td>19.58(0.63)</td>
<td>1.93(0.14)</td>
</tr>
<tr>
<td>Intact EHC 5% bile diversion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>Control (6)</td>
<td>89.70(1.13)</td>
<td>8.18(0.97)</td>
</tr>
<tr>
<td>Drug (11)</td>
<td>86.60(0.67)</td>
<td>11.88(0.67)</td>
<td>P &lt; 0.01</td>
</tr>
<tr>
<td>B</td>
<td>Control (3)</td>
<td>88.35(1.28)</td>
<td>10.07(1.00)</td>
</tr>
<tr>
<td>Drug (5)</td>
<td>86.16(0.44)</td>
<td>12.56(0.72)</td>
<td>NS</td>
</tr>
<tr>
<td>D</td>
<td>Control (19)</td>
<td>86.99(0.60)</td>
<td>10.96(0.57)</td>
</tr>
<tr>
<td>Drug (18)</td>
<td>87.10(0.56)</td>
<td>11.52(0.57)</td>
<td>P &lt; 0.001</td>
</tr>
</tbody>
</table>

In all studies phenobarbital decreased the proportion of cholesterol in bile. Significant reduction was present in three of six studies. In four of six studies a slight decrease in the proportion of bile salts was seen. Five of six studies showed a slight increase in the proportion of phospholipid. The bile salt to cholesterol ratio was increased by the drug in each study.

* Mean ± SEM.

** NS not significant by Student’s t test (21).

Phenobarbital, however, raised this level of “maximal bile acid synthesis” well above the normal range (Fig. 6) in all three monkeys suggesting that 7α-hydroxylation of cholesterol was enhanced. Normally bile acid synthesis is significantly inhibited by feedback inhibition of bile salt returned to the liver via the portal vein in the intact animal (4). It is clear from the relation between bile acid synthesis rate and the rate at which bile salts return to the liver, as illustrated in control monkeys by the shaded zone in Fig. 6, that above a critical

TABLE IV
Statistical Analysis of All Experiments

<table>
<thead>
<tr>
<th>P values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flow</td>
</tr>
<tr>
<td>Bile salt</td>
</tr>
<tr>
<td>Bile salt</td>
</tr>
<tr>
<td>Control vs. drug</td>
</tr>
<tr>
<td>Intact EHC (5% diversion vs. total bile fistula)</td>
</tr>
<tr>
<td>Interaction</td>
</tr>
</tbody>
</table>

168 R. N. Redinger and D. M. Small
cal rate of bile salt return (approximately 7 mmol/24 h) bile acid synthesis normally becomes increasingly suppressed as the rate of return is increased. One would, therefore, expect bile acid synthesis to be largely suppressed or completely inhibited by increased bile salt secretion produced by phenobarbital in animals with physiologically intact EHC since more bile salt would be reabsorbed and returned to the liver. This, however, was not the case in phenobarbital-treated animals. When bile acid synthesis was plotted against bile salt returned to the liver (Fig. 6), our animals, during the control period, followed the normal relationship of return vs. synthesis. During drug treatment, however, in spite of increased rate of bile salt returned to the liver, bile acid synthesis was increased rather than decreased. Thus, phenobarbital partly overcomes the normal control of bile acid synthesis exerted by the hepatic return rate of bile salts. Furthermore, increased bile acid synthesis resulting from phenobarbital administration coupled with unaltered fecal loss resulted in an expanded bile-salt pool size in the two animals with intact EHC in which the pool was measured before and during drug treatment.

It is known that phenobarbital-induced proliferation of the smooth endoplasmic reticulum is characterized by an increase in both phospholipid and protein content, as well as enzyme induction (7). Young, Powell, and McMillan (8) have recently shown that hepatic microsomal preparations from male adult rats, pretreated with 70 mg/kg per day phenobarbital given intraperitoneally, exhibited significant increases in the specific activity of the enzyme governing phosphatidylcholine synthesis by sequential methylation of phosphatidylethanolamine. In addition, they also showed that in vivo incorporation of [methyl-\(^3\)H] from L-[methyl-\(^3\)H]methionine into hepatic microsomal phosphatidylcholine was increased more than threefold over control animals while comparable increases in serum phospholipids were not seen. Thus, the enhanced phospholipid secretion into bile seen in all our experiments supports the above findings and suggests that phospholipid synthesis along with that of bile acid was enhanced by phenobarbital administration.

The secretion of the other major bile lipid, cholesterol, was not increased as a result of phenobarbital treatment in the monkey. Jones and Armstrong (40) as well as Wade, Hirata, and Sakamoto (41) have shown that hepatic microsomal preparations from rats pretreated with phenobarbital (dose 100 mg/kg intra-

---

\(^4\) That phenobarbital did produce hypertrophy of the smooth endoplasmic reticulum at the doses we used was verified by liver biopsy and electron microscopic examination. (Courtesy of Dr. Jerry Trier, Department of Medicine.)

![Figure 5](image-url)
salt synthesis in the rat (3), our experiments in monkeys (1, 11) have shown that the rate of bile salt return to the liver controls the level of the bile acid synthesis. Other investigators (44) have concluded that bile salts exert feedback inhibition on 3-hydroxy-3-methylglutamyl-CoA (HMG-CoA) reductase, the rate-limiting step in cholesterol synthesis. Phenobarbital has been shown to increase the activity of both hepatic enzymes (6, 41), and in our experiments to result in increased bile salt secretion. The increased return of bile salt to the liver could have theoretically resulted in inhibition of cholesterol synthesis. This appears unlikely from experiments carried out on various animal species subjected to acute biliary tract obstruction. In the rat, Weis and Dietschy (45), have shown that HMG-CoA reductase activity is increased along with cholesterol synthesis during acute biliary-tract obstruction. At the same time the amount of bile salt in the liver of the obstructed animals increased threefold (45). In experiments carried out on the Rhesus monkey we have found that bile salt synthesis was inhibited during acute biliary-tract obstruction probably as a result of bile salt retained within the liver during obstruction (46). Further, during the postobstructive period bile salt synthesis remains depressed but cholesterol secretion is markedly increased (46). Thus, it seems improbable that bile salts in the liver directly inhibit hepatic cholesterol synthesis.

Since both bile salt and phospholipid to cholesterol ratios were significantly increased by phenobarbital in all our studies, a very significant lowering of the relative concentration of cholesterol in bile was found in phenobarbital-treated animals. Thus, bile was formed which had a greater cholesterol-holding capacity. These results are noteworthy in that they may have significant therapeutic implications in the treatment or prevention of human cholelithiasis. By improving bile composition, the prevention of gallstones in high risk populations (47) may be possible. Further, the dissolution of "silent" gallstones may also be possible (48). We have consequently undertaken a clinical study to examine the effects of phenobarbital upon human hepatobiliary physi-
ology and to determine whether a safe medical regimen of phenobarbital administration would be beneficial to patients with abnormal bile or cholesterol cholelithiasis.

ACKNOWLEDGMENTS

This work was supported by NIH Grant AM 11453.

REFERENCES


barbital on the conversion of cholesterol to taurocholic acid. Bile acids and steroids 204. Eur. J. Biochem. 6: 293.


